Physician profile
Gregory G Pendell
NPI 1831172121
$19,213.90
in general payments reported to CMS, 2019-2025
38 companies · $3,507 in 2025
The $3,507 reported for 2025 was more than what 79% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,992 · 2020: $1,914 · 2021: $3,019 · 2022: $2,782 · 2023: $2,849 · 2024: $3,151 · 2025: $3,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,395 · Consulting Fee: $82.67 · Education: $29.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,395.18 |
| Consulting Fee | $82.67 |
| Education | $29.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,141.65 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $2,475.93 | 2019-2025 | Dupixent |
| Csl Behring | $2,364.01 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Glaxosmithkline, LLC. | $1,451.79 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,308.71 | 2019-2025 | |
| Genentech USA, INC. | $1,038.78 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $1,006.70 | 2020-2025 | Takhzyro, Cuvitru, Glassia |
| Grifols USA, LLC | $946.12 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $657.66 | 2019-2025 | |
| Pharming Healthcare, INC. | $512.40 | 2019-2025 | Ruconest |
| Pfizer INC. | $511.50 | 2019-2025 | |
| Amgen INC. | $499.53 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $410.53 | 2019-2025 | |
| Kaleo, INC. | $400.45 | 2019-2024 | Auvi-Q |
| Shire North American Group INC | $319.33 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Pendell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.